 GlaxoSmithKline profits fall 9% last year to Â£6.2bn ($11.5bn) Firm is confident its new drug pipeline will deliver profits despite failure of obesity drug . Firm relying on new treatments for conditions such as cancer, diabetes, depression, HIV/AIDS and allergies to lift the pace of sales growth after several disappointing years . In early afternoon trade in London the company share price was down 1% at 1218 pence . In 2004, global sales were up 1% in 2004 .